secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2025-12-16T23:59:59+00:00
Accession:  0001829126-25-010037
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 5.08, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KALA BIO CEO Lazar sells Series AAA preferred rights; consultant hired for strategic alternatives
--------------------------------------------------------------------------------

- Annual meeting set for Jan 30, 2026; stockholder proposals and director nominations due Dec 27, 2025.
- David Lazar sold his rights to purchase Series AAA Preferred Shares (up to $4.2M) to unaffiliated AK Holdings Group Inc.
- Company retains consultant, a principal of AK Holdings, to advise on identifying and consummating a strategic alternative transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000182912625010037/0001829126-25-010037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000182912625010037/kalabio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-010037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer